ESTRO 2023 - Abstract Book

S1135

Digital Posters

ESTRO 2023

NAR score was calculated for 81 patients. A first model including only NAR score had an area under curve (AUC) of 0.81; NAR score had a coefficient of 0.076 (CI 95% 0.028-0.125, p = 0.002). Owing to the intrinsic relation between low NAR score and pCR, a second model omitting the later patients was created. AUC of the second model was 0.74 with a coefficient of 0.062 (CI 95% 0.014-0.110, p = 0.002). The optimal cutoff point was estimated to be 20.4, with a Youden index of 0.52. Patients with NAR score < 20.4 had a 3y-OS of 88.5% (CI 95% 76-94.7) vs 33.9% (CI 95% 12.5-57.1) for NAR score ≥ 20.4 (p

logrank < 0.0001) (Figure 2). Figure 2.- OS by NAR score

Conclusion TNT is an effective treatment, exhibiting excellent results in the patients achieving pCR. NAR score offers good discrimination for 3y-OS.

PO-1406 Re-irradiation in locally recurrent rectal cancer: a national survey of the AIRO GI study group

G. MANTELLO 1 , E. Galofaro 1 , C. Di Carlo 1 , S. Montrone 2 , L. Caravatta 3 , A. De Paoli 4 , M.A. Gambacorta 5 , D. Genovesi 3 , M. Lupattelli 6 , G. Macchia 7 , R.M. Niespolo 8 , F. Valvo 9 , D. Arpa 10 , M. Scricciolo 11 , V. Chiloiro 5 , G. Montesi 12 , A. Pontoriero 13 , V. Donato 14 , P. Franco 15 1 Azienda Ospedaliero Universitaria delle Marche, Radiotherapy Department, Ancona, Italy; 2 Pisa University, Department of Radiotherapy, Pisa, Italy; 3 SS Annunziata Hospital, Department of Radiation Oncology, Chieti, Italy; 4 Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Division of Radiation Oncology, Aviano, Italy; 5 Università Cattolica del Sacro Cuore, Departments of Radiation Therapy, Roma, Italy; 6 University of Perugia and Perugia General Hospital, Radiation Oncology Section, Perugia, Italy; 7 Fondazione di Ricerca e Cura 'Giovanni Paolo II'- Catholic University of Sacred Heart, Radiotherapy Unit, Campobasso, Italy; 8 Azienda Ospedaliera San Gerardo, Radiotherpy Unit, Monza, Italy; 9 Fondazione CNAO, National Center of Oncological Hadrontherapy, Pavia, Italy; 10 IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Radiotherapy Unit, Meldola, Italy; 11 Ospedale dell’Angelo, UOC di Radioterapia Oncologica Mestre, Venezia Mestre, Italy; 12 ULSS5, Radiotherapy Unit, Rovigo, Italy; 13 University of Messina, Radiation Oncology Unit - Department of Biomedical, Dental Science and Morphological and Functional Images, Messina, Italy; 14 San Camillo-Forlanini Hospital, Radiation Oncology Division, Oncology and Speciality Medicine Department, Roma, Italy; 15 University of Eastern Piedmont, Maggiore della Carità University Hospital, Department of Translational Medicine, Department of Radiation Oncology, Novara, Italy